161 related articles for article (PubMed ID: 12846921)
1. The drug budget silo mentality in Europe: an overview.
Garrison L; Towse A
Value Health; 2003; 6 Suppl 1():S1-9. PubMed ID: 12846921
[No Abstract] [Full Text] [Related]
2. Moving beyond the drug budget silo mentality in Europe.
Drummond M; Jönsson B
Value Health; 2003; 6 Suppl 1():S74-7. PubMed ID: 12846928
[No Abstract] [Full Text] [Related]
3. The drug budget silo mentality: the French case.
Le Pen C
Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
[TBL] [Abstract][Full Text] [Related]
4. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
Schwermann T; Greiner W; v d Schulenburg JM
Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
[TBL] [Abstract][Full Text] [Related]
5. The drug budget silo mentality: the Dutch case.
Koopmanschap MA; Rutten FF
Value Health; 2003; 6 Suppl 1():S46-51. PubMed ID: 12846925
[TBL] [Abstract][Full Text] [Related]
6. [Separate pharmaceutical budgets: skating on thin ice].
Egberts AC; de Boer A
Ned Tijdschr Geneeskd; 2010; 154(51-52):A3004. PubMed ID: 21211087
[TBL] [Abstract][Full Text] [Related]
7. [Drug atlas corrects political reproaches: why drug expenditures of GKV are really increasing].
Schmidt K
MMW Fortschr Med; 2007 Mar; 149(9):50-1. PubMed ID: 17612254
[No Abstract] [Full Text] [Related]
8. Spending on pharmaceuticals in Italy: macro constraints with local autonomy.
Mapelli V; Lucioni C
Value Health; 2003; 6 Suppl 1():S31-45. PubMed ID: 12846924
[TBL] [Abstract][Full Text] [Related]
9. [Drug utilization and pharmaceutical cost-containment in germany-perspectives 1 year after enactment of the GMG].
Schlander M
Med Klin (Munich); 2005 Jun; 100(6):314-24. PubMed ID: 15968483
[TBL] [Abstract][Full Text] [Related]
10. Management of cost and utilization of pharmaceuticals in Germany.
von der Schulenburg JM
Health Policy; 1997 Sep; 41 Suppl():S45-53. PubMed ID: 10174473
[TBL] [Abstract][Full Text] [Related]
11. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
Antoñanzas F
Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical economy and the economic assessment of drugs in France.
le Pen C
Soc Sci Med; 1997 Aug; 45(4):635-43. PubMed ID: 9226787
[TBL] [Abstract][Full Text] [Related]
13. [European court. Drug budgets of physicians remain reduced].
MMW Fortschr Med; 2004 Mar; 146(13):57. PubMed ID: 15219133
[No Abstract] [Full Text] [Related]
14. The NHS medicines bill: running out of control?
Drug Ther Bull; 2015 Jun; 53(6):61. PubMed ID: 26045094
[No Abstract] [Full Text] [Related]
15. Drifting policies are wasting billions.
Suh GH
Int Psychogeriatr; 2012 Mar; 24(3):343-5. PubMed ID: 22078134
[No Abstract] [Full Text] [Related]
16. UK budgetary systems and new health-care technologies.
McGuire A; Litt M
Value Health; 2003; 6 Suppl 1():S64-73. PubMed ID: 12846927
[TBL] [Abstract][Full Text] [Related]
17. Lessons from Europe on the funding of healthcare.
Evans RG
CHAC Rev; 1995; 23(3):9-11. PubMed ID: 10152517
[No Abstract] [Full Text] [Related]
18. [The need for joint evaluation of pharmaceutical expenditure and the health outcomes obtained].
Soto Álvarez J
Gac Sanit; 2011; 25(3):257. PubMed ID: 21459490
[No Abstract] [Full Text] [Related]
19. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies.
Hailey D
Soc Sci Med; 1997 Aug; 45(4):563-81. PubMed ID: 9226782
[TBL] [Abstract][Full Text] [Related]
20. Drug-altered states. As pharmaceutical spending continues to soar, state legislatures are taking bold steps to rein in their costs.
Tieman J
Mod Healthc; 2002 Apr; 32(17):28-31. PubMed ID: 12024771
[No Abstract] [Full Text] [Related]
[Next] [New Search]
